Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Urologic / Genitourinary Cancers

14 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Other

Breast
Head/Neck
Prostate

VICCSUPP1224

11/19/2012

Osteonecrosis of the Jaw Case (ONJ) Registry

Other

Prostate

URO70807-M

05/10/2012

Men's Eating and Living Study: A Randomized trial of diet to alter disease progression in prostste cancer patients on active surveillance

Other

Bladder

VICCURO1143

11/01/2011

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial. Protocol No. 36911

Supportive Care

Breast
Colon
Lung
Prostate
Rectal

VICCREACH1341

09/05/2013

Using a Tailored Navigation Intervention to Prepare Patients and Their Support Person for the Journey at Time of Cancer Diagnosis and at Transition into Survivorship

Treatment

Prostate

CTSUALLIANCEURO031201-M

11/21/2014

URO A031201: Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Treatment

Urologic

VICCPHI1449

10/27/2014

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer

Treatment

Prostate

VICCURO1450

08/13/2014

PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

Treatment

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

Breast
Colon
Lung
Ovarian
Pancreatic
Prostate
Rectal

VICCPHI1394

04/17/2014

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

Treatment

Bladder

VICCURO1382

02/10/2014

A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer

Treatment

Bladder

VICCURO1367

01/27/2014

An Integrated Phase II/III Open Label, Randomized, Parallel and Controlled Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients with Non-Muscle Invasive Bladder Carcinoma in Situ Disease ("NMIBCis", Meaning CIS and CIS with Ta and/or T1) and Who Have Failed BCG Therapy and Refused Cystectomy

Treatment

Prostate

VICCURO1260

03/19/2013

A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

Treatment

Adrenocortical
Bladder
Breast
Cervical
Colon
Dermatologic
Esophageal
GIST
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Liver
Lung
Multiple Myeloma
Neuroendocrine
Ovarian
Pancreatic
Prostate
Rectal
Sarcoma
Small Cell
Uterine

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Treatment

Prostate

CTSUUROC90203-M

11/05/2007

A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer